AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3011310
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nedocromil sodium
Trial: 3011310
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg nedocromil sodium
Trial: 31951148
Drug: Limited controlling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited controlling method (L-K)
Trial: 20304566
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 25 Gy and lower doses (20 Gy and 15 Gy)
Trial: 15647648
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (n=28)
Trial: 15647648
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (n=30)
Trial: 15647648
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (n=27)
Trial: 12038875
Drug: Newer hypnotics
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer hypnotics
Trial: 7666101
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg twice daily on days 2 and 3 and placebo on days 4 to 6
Trial: 7666101
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg twice daily on days 2 to 6
Trial: 9557622
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy for ALL
Trial: 1131555
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy conducted by medical students
Trial: 31846980
Drug: Active tACS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tACS (20 daily 40-min sessions, 77.5-Hz, 15-mA)
Trial: 23743976
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg BID (DE 110)
Trial: 23743976
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg BID (DE 150)
Trial: 19057983
Drug: ALA-PDT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT with 60 mg/kg and red laser light (1,000 J/cm)
Trial: 19057983
Drug: ALA-PDT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT with 30 mg/kg
Trial: 19057983
Drug: ALA-PDT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT with 60 mg/kg and red laser light
Trial: 24718066
Drug: Kineflex-L Disc
RxNorm normalized name: Sus scrofa intervertebral disc preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kineflex-L Disc (investigational group)
Trial: 17209164
Drug: Intradiscal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal and intraforaminal injections of a steroid, an anesthetic, and O(2)-O(3) mixture (group B)
Trial: 17209164
Drug: Intradiscal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal and intraforaminal injections of a steroid and an anesthetic (group A)
Trial: 10335537
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with birthweight < 2500 g
Trial: 7656629
Drug: Local radiotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local radiotherapy (7 Gy, three daily sessions, 10 to 15 days after thoracoscopy)
Trial: 2789920
Drug: APD 30
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 30 mg single dose on day 1 (group A, n = 9)
Trial: 2789920
Drug: APD 30
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 30 mg two consecutive doses on days 1 and 2 (group B, n = 9)
Trial: 2789920
Drug: APD 60
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 60 mg single dose on day 1 (group C, n = 9)
Trial: 23793945
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide (10 mg/h)
Trial: 23793945
Drug: Bolus of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of furosemide (20 mg/6 h)
Trial: 23793945
Drug: Bolus of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of furosemide (20 mg/8 h)
Trial: 21494186
Drug: Probiotic fermented
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic fermented milk administered 3 times daily for 8 weeks
Trial: 21494186
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 3 times daily for 8 weeks
Trial: 12610049
Drug: 1.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/day ramipril
Trial: 16186399
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day ramipril
Trial: 9890408
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg/day for first 4 weeks, then 10 mg/day for second 4 weeks)
Trial: 27702624
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg intravitreal aflibercept injections (IAIs)
Trial: 24052800
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation treatment
Trial: 24052800
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (placebo)
Trial: 21263308
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (10% Travasol)
Trial: 15039148
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg orally every 6 h for 3 days)
Trial: 15039148
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (10% Travasol) with dexamethasone
Trial: 11511425
Drug: NPR‐C receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPR‐C receptor density in patients with HF (class III‐IV)
Trial: 11511425
Drug: NPR‐C receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPR‐C receptor density in patients with HF (class I‐II)
Trial: 11511425
Drug: NPR‐C receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPR‐C receptor density in healthy controls
Trial: 11511425
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of NPR‐C receptor density between class III‐IV HF patients and controls
Trial: 11511425
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of NPR‐C receptor density between class III‐IV HF patients and class I‐II HF patients
Trial: 29135656
Drug: 3-monthly creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-monthly creatinine clearance (CrCl) monitoring
Trial: 29135656
Drug: 6-monthly creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-monthly creatinine clearance (CrCl) monitoring
Trial: 24251386
Drug: Functionally orientated
RxNorm normalized name: Papaver orientale seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functionally orientated treatment based on the shortened dental arch concept (SDA)
Trial: 18711405
Drug: CABG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABG with intramuscular or intracoronary administration of BMCs
Trial: 15866056
Drug: Nondiabetic control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondiabetic control (no insulin)
Trial: 2223423
Drug: CsA concentrations
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA concentrations measured by h.p.l.c.
Trial: 31957070
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g amoxicillin pre-operative and 500 mg thrice daily on days 1-3 post-operative
Trial: 30824647
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg once every 2 weeks
Trial: 30824647
Drug: Baseline CRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline CRP levels > 2.87 mg/l
Trial: 28067745
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride XR 60 mg daily
Trial: 22185811
Drug: mpHBV (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mpHBV (10 µg HBsAg)
Trial: 22185811
Drug: RECOMBIVAX HB™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECOMBIVAX HB™ (10 µg HBsAg)
Trial: 22185811
Drug: ENGERIX‐B™ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENGERIX‐B™ (20 µg HBsAg)
Trial: 18940221
Drug: Encepur Children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encepur Children (third dose)
Trial: 17075252
Drug: 0.025% levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% levocabastine hydrochloride ophthalmic suspension
Trial: 2454372
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 to 200 mg)
Trial: 3312502
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 320 mg)
Trial: 2454372
Drug: Pindolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5 to 20 mg)
Trial: 2454372
Drug: Labetalol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (50 to 400 mg)
Trial: 29423840
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (λ627 ± 10 nm) with an energy density of 10 J/cm2 for 6 days
Trial: 29423840
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (LED therapy turned off) for 6 days
Trial: 23225211
Drug: Lycopene-enriched virgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-enriched virgin olive oil (7 mg lycopene day(‐1))
Trial: 18274695
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.1 mg/d)
Trial: 3602014
Drug: Pentoxifylline ('Trental'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline ('Trental' 400) 400 mg 3-times daily for two 3-month periods interrupted by a 4-week wash-out period
Trial: 18313028
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection into the masseter muscle
Trial: 11725598
Drug: Shuttle walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shuttle walking test with various orthopaedic treatments
Trial: 25311594
Drug: Traditional voice
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional voice therapy
Trial: 11758004
Drug: Chlamydia pneumoniae
RxNorm normalized name: Chlamydia pneumoniae Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in CAD patients with CRF
Trial: 11758004
Drug: Chlamydia pneumoniae
RxNorm normalized name: Chlamydia pneumoniae Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in all CAD patients
Trial: 11758004
Drug: Mean antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean antibody index of IgG in CAD patients
Trial: 11758004
Drug: Elevated IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated IgG antibody index
Trial: 7951567
Drug: Euglycemic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NGT subjects (n = 13)
Trial: 7951567
Drug: Euglycemic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in BGI subjects (n = 12)
Trial: 7951567
Drug: Euglycemic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NIDDM subjects (n = 12)
Trial: 12074223
Drug: Slow flow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow flow rate (161 sec/mL) of 0.3 mL local anesthetic solution
Trial: 12074223
Drug: Fast flow
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast flow rate (29 sec/mL) of 0.3 mL local anesthetic solution
Trial: 8083715
Drug: Front-loading consolidation
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-loading consolidation therapy (6 MTX/Ara-C infusions at 3-week intervals from 7th to 19th week)
Trial: 8083715
Drug: Standard consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard consolidation therapy (6 MTX/Ara-C infusions every 12 weeks from 7th to 67th week)
Trial: 22304627
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg of r-hCG
Trial: 22304627
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg of r-hCG
Trial: 18756184
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of oral pentavalent rotavirus vaccine (PRV) and oral poliovirus vaccine (OPV)
Trial: 1371633
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg p.o.
Trial: 1371633
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg i.m.
Trial: 29332637
Drug: Disorder-oriented multicomponent
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disorder-oriented multicomponent group therapy (12 sessions of 90 minutes each) integrating interactive psychoeducation, gut-directed hypnotherapy, and open group phases.
Trial: 20410466
Drug: Therapy-based oncology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy-based oncology RCTs
Trial: 11575897
Drug: Terbutaline (Bricanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (Bricanyl Turbuhaler 0.5 mg)
Trial: 9272401
Drug: Yohimbine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (3 x 6 mg per day)
Trial: 9272401
Drug: Anetholtrithione (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetholtrithione (3 x 25 mg per day)
Trial: 7942085
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with estradiol and estradiol plus medroxyprogesterone acetate
Trial: 3367488
Drug: HPV‐77 DE‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐77 DE‐5 rubella virus vaccine
Trial: 3367488
Drug: HPV‐77 DK‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐77 DK‐12 rubella virus vaccine
Trial: 56908
Drug: Epontol (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epontol (7 mg/kg i.v.)
Trial: 56908
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection of Epontol (7 mg/kg) and infusion (21 mg/kg during 15 min)
Trial: 56908
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection of Epontol (7 mg/kg) and suxamethonium (0.5 mg/kg)
Trial: 31893588
Drug: Control (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (traditional balanced salt solution-infused technique)
Trial: 25365122
Drug: Minimal-treatment home
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-treatment home study control condition
Trial: 23057434
Drug: Milk (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (5 mL)
Trial: 23057434
Drug: Glucose (25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (25% glucose water, 5 mL)
Trial: 23057434
Drug: Water (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (5 mL distilled water)
Trial: 21665265
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus a glycoprotein IIb/IIIa inhibitor (GPI)
Trial: 16912354
Drug: Subcutaneous extralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous extralesional triamcinolone acetonide injection (0.3 mL, 10 mg/mL)
Trial: 16912354
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (lid hygiene, warm compresses, chloramphenicol 1% ointment 4 times a day)
Trial: 16912354
Drug: Subcutaneous extralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous extralesional triamcinolone acetonide injection
Trial: 14755153
Drug: Probiotics in
RxNorm normalized name: Niacinamide 1.00 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL LIQUID [Ambling Plant Probiotics Into Nature Essence I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics in capsules
Trial: 11985972
Drug: Prophylaxis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis group (2 g of cephtazidime intravenously 30 minutes before ERCP)
Trial: 9271042
Drug: DTPa-IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV vaccine
Trial: 9271042
Drug: DTPa-IPV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV and Hib vaccine (mixed)
Trial: 9271042
Drug: DTPa-IPV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV and Hib vaccine (separate)
Trial: 9271042
Drug: DTPw-IPV-Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-IPV-Hib vaccine
Trial: 3366075
Drug: Intravenous fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fenoterol (bolus injection and continuous infusion)
Trial: 3366075
Drug: Intravenous fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fenoterol
Trial: 3366075
Drug: Simultaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous and continuous intravenous administration of fenoterol and theophylline
Trial: 25053749
Drug: FroDex25 (frovatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FroDex25 (frovatriptan 2.5 mg + dexketoprofen 25 mg)
Trial: 21447908
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training program twice a week for 6 weeks
Trial: 15381675
Drug: L-NAME (66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (66 microg/kg per min for 30 minutes)
Trial: 15381675
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 g TID) plus ramipril (10 mg QD)
Trial: 11528242
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 40 mg of iron during the first ten HD sessions (n = 12)
Trial: 11528242
Drug: Weekly injection
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injection of 40 mg of iron for 10 weeks (n = 12)
Trial: 9623154
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of sodium cromoglycate through a spacer device
Trial: 7940732
Drug: OKT3-based immunoprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3-based immunoprophylaxis with steroids and azathioprine for 14 days, cyclosporine introduced on day 11 posttransplant.
Trial: 7940732
Drug: Cyclosporine-based immunoprophylaxis
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine-based immunoprophylaxis with steroids and azathioprine.
Trial: 3349748
Drug: Procan SR
RxNorm normalized name: Procan SR
DrugBank: Procainamide (DB01035)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Procan SR 1 g
Trial: 3349748
Drug: Pronestyl-SR 1
RxNorm normalized name: procainamide hydrochloride Oral Tablet [Pronestyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pronestyl-SR 1 g
Trial: 25743733
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care with an aroma solution
Trial: 19288431
Drug: Intensity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity of therapy increased from 3 to 5 hours